PROGNOSTIC IMPACT OF ABERRANT SURFACE MARKERS EXPRESSION IN T- ACUTE LYMPHOBLASTIC LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. Awad S. 06/09/16; 134502; PB1602
Dr. Shady Awad
Contributions
Contributions
Abstract
Abstract: PB1602
Type: Publication Only
Background
Immunophenotyping is very important in diagnosis, and risk stratification of T-ALL with MRD proven to be the strongest prognostic indicator. Few small-scale studies have reported aberrant CD markers (CD10-CD34-CD13/CD33) in T-ALL with much conflict about its prognostic impact.
Aims
To study aberrant expression of CD10, CD34 and myeloid associated antigens (CD13/CD33) in T-ALL patients and to investigate its correlation with clinical and biologic features, treatment response (MRD) and overall survival.
Methods
This study included 62 newly diagnosed T-ALL patients from the National Cancer Institute (NCI) in Egypt during the time period from September 2012 to December 2014. All patients had undergone full history, thorough clinical examination, complete blood count (CBC), and BM aspiration. Immunophenotypic markers and minimal residual disease (MRD) at fixed time points in BM aspirate samples were studied by four-color flowcytometry EPICS XL (Coulter Corporation, Hialeah, FL, USA).
Results
Patients were classified into three phenotypes based on their immunophenotyping characteristics (CD3 cytoplasmic/surface, CD1a, CD4/CD8 expression): early T (16/62, 25.8%), T-intermediate (39/62, 63%), and T- late (7/62, 11.2 %). Comparisons of different phenotypes regarding clinical factors (Age, Sex, initial mediastinal mass), hematological (Hemoglobin, leucocytes counts (TLC), Platelet counts, initial BM blast%), aberrant CD markers (CD10, CD34, CD13/CD33), MRD (Day 15, 33 and 56) and overall survival revealed significant variations regarding: TLC where the highest was T-late phenotype (P= 0.014), MRD D33 (P= 0.039) and MRD D56 (P= 0.007) where T-late phenotype shows a better outcome. CD10 was expressed on 17/62 (27.4%), CD13 and/or CD33 on 10/62 (16.1%), CD34 on 15/62 (24.2%) of cases and co-expression of CD10 and CD34 on 5/62 (8%). Significant associations were found aberrant markers and different phenotypic groups where CD10+CD34+ phenotype and CD13/CD33 occur almost exclusively in early-T groups (P= 0.007 and 0.002 respectively). CD10 shows borderline significant better MRD outcome at D33 (P=0.057) and also slightly better overall survival. CD34 shows significantly worse MRD D33 (P=0.045) but no correlation with OS. Though all five patients with CD10+CD34+ phenotype shows MRD<0.01 by D33 and then after, no significant correlation was found with MRD nor OS; which maybe be explained by small patient number. CD13/CD33 expression shows significant correlation with worse MRD D33 (P=0.017) with worse -but not significant- OS.
Conclusion
Immunophenotypic groups and aberrant expression (CD10, CD34, CD10+CD34 and CD13/CD33) have an important prognostic value in T-ALL, which is evident by their effect on MRD D33, D56 and OS.
Session topic: E-poster
Keyword(s): CD33, CD34, MRD, T-ALL
Type: Publication Only
Background
Immunophenotyping is very important in diagnosis, and risk stratification of T-ALL with MRD proven to be the strongest prognostic indicator. Few small-scale studies have reported aberrant CD markers (CD10-CD34-CD13/CD33) in T-ALL with much conflict about its prognostic impact.
Aims
To study aberrant expression of CD10, CD34 and myeloid associated antigens (CD13/CD33) in T-ALL patients and to investigate its correlation with clinical and biologic features, treatment response (MRD) and overall survival.
Methods
This study included 62 newly diagnosed T-ALL patients from the National Cancer Institute (NCI) in Egypt during the time period from September 2012 to December 2014. All patients had undergone full history, thorough clinical examination, complete blood count (CBC), and BM aspiration. Immunophenotypic markers and minimal residual disease (MRD) at fixed time points in BM aspirate samples were studied by four-color flowcytometry EPICS XL (Coulter Corporation, Hialeah, FL, USA).
Results
Patients were classified into three phenotypes based on their immunophenotyping characteristics (CD3 cytoplasmic/surface, CD1a, CD4/CD8 expression): early T (16/62, 25.8%), T-intermediate (39/62, 63%), and T- late (7/62, 11.2 %). Comparisons of different phenotypes regarding clinical factors (Age, Sex, initial mediastinal mass), hematological (Hemoglobin, leucocytes counts (TLC), Platelet counts, initial BM blast%), aberrant CD markers (CD10, CD34, CD13/CD33), MRD (Day 15, 33 and 56) and overall survival revealed significant variations regarding: TLC where the highest was T-late phenotype (P= 0.014), MRD D33 (P= 0.039) and MRD D56 (P= 0.007) where T-late phenotype shows a better outcome. CD10 was expressed on 17/62 (27.4%), CD13 and/or CD33 on 10/62 (16.1%), CD34 on 15/62 (24.2%) of cases and co-expression of CD10 and CD34 on 5/62 (8%). Significant associations were found aberrant markers and different phenotypic groups where CD10+CD34+ phenotype and CD13/CD33 occur almost exclusively in early-T groups (P= 0.007 and 0.002 respectively). CD10 shows borderline significant better MRD outcome at D33 (P=0.057) and also slightly better overall survival. CD34 shows significantly worse MRD D33 (P=0.045) but no correlation with OS. Though all five patients with CD10+CD34+ phenotype shows MRD<0.01 by D33 and then after, no significant correlation was found with MRD nor OS; which maybe be explained by small patient number. CD13/CD33 expression shows significant correlation with worse MRD D33 (P=0.017) with worse -but not significant- OS.
Conclusion
Immunophenotypic groups and aberrant expression (CD10, CD34, CD10+CD34 and CD13/CD33) have an important prognostic value in T-ALL, which is evident by their effect on MRD D33, D56 and OS.
Session topic: E-poster
Keyword(s): CD33, CD34, MRD, T-ALL
Abstract: PB1602
Type: Publication Only
Background
Immunophenotyping is very important in diagnosis, and risk stratification of T-ALL with MRD proven to be the strongest prognostic indicator. Few small-scale studies have reported aberrant CD markers (CD10-CD34-CD13/CD33) in T-ALL with much conflict about its prognostic impact.
Aims
To study aberrant expression of CD10, CD34 and myeloid associated antigens (CD13/CD33) in T-ALL patients and to investigate its correlation with clinical and biologic features, treatment response (MRD) and overall survival.
Methods
This study included 62 newly diagnosed T-ALL patients from the National Cancer Institute (NCI) in Egypt during the time period from September 2012 to December 2014. All patients had undergone full history, thorough clinical examination, complete blood count (CBC), and BM aspiration. Immunophenotypic markers and minimal residual disease (MRD) at fixed time points in BM aspirate samples were studied by four-color flowcytometry EPICS XL (Coulter Corporation, Hialeah, FL, USA).
Results
Patients were classified into three phenotypes based on their immunophenotyping characteristics (CD3 cytoplasmic/surface, CD1a, CD4/CD8 expression): early T (16/62, 25.8%), T-intermediate (39/62, 63%), and T- late (7/62, 11.2 %). Comparisons of different phenotypes regarding clinical factors (Age, Sex, initial mediastinal mass), hematological (Hemoglobin, leucocytes counts (TLC), Platelet counts, initial BM blast%), aberrant CD markers (CD10, CD34, CD13/CD33), MRD (Day 15, 33 and 56) and overall survival revealed significant variations regarding: TLC where the highest was T-late phenotype (P= 0.014), MRD D33 (P= 0.039) and MRD D56 (P= 0.007) where T-late phenotype shows a better outcome. CD10 was expressed on 17/62 (27.4%), CD13 and/or CD33 on 10/62 (16.1%), CD34 on 15/62 (24.2%) of cases and co-expression of CD10 and CD34 on 5/62 (8%). Significant associations were found aberrant markers and different phenotypic groups where CD10+CD34+ phenotype and CD13/CD33 occur almost exclusively in early-T groups (P= 0.007 and 0.002 respectively). CD10 shows borderline significant better MRD outcome at D33 (P=0.057) and also slightly better overall survival. CD34 shows significantly worse MRD D33 (P=0.045) but no correlation with OS. Though all five patients with CD10+CD34+ phenotype shows MRD<0.01 by D33 and then after, no significant correlation was found with MRD nor OS; which maybe be explained by small patient number. CD13/CD33 expression shows significant correlation with worse MRD D33 (P=0.017) with worse -but not significant- OS.
Conclusion
Immunophenotypic groups and aberrant expression (CD10, CD34, CD10+CD34 and CD13/CD33) have an important prognostic value in T-ALL, which is evident by their effect on MRD D33, D56 and OS.
Session topic: E-poster
Keyword(s): CD33, CD34, MRD, T-ALL
Type: Publication Only
Background
Immunophenotyping is very important in diagnosis, and risk stratification of T-ALL with MRD proven to be the strongest prognostic indicator. Few small-scale studies have reported aberrant CD markers (CD10-CD34-CD13/CD33) in T-ALL with much conflict about its prognostic impact.
Aims
To study aberrant expression of CD10, CD34 and myeloid associated antigens (CD13/CD33) in T-ALL patients and to investigate its correlation with clinical and biologic features, treatment response (MRD) and overall survival.
Methods
This study included 62 newly diagnosed T-ALL patients from the National Cancer Institute (NCI) in Egypt during the time period from September 2012 to December 2014. All patients had undergone full history, thorough clinical examination, complete blood count (CBC), and BM aspiration. Immunophenotypic markers and minimal residual disease (MRD) at fixed time points in BM aspirate samples were studied by four-color flowcytometry EPICS XL (Coulter Corporation, Hialeah, FL, USA).
Results
Patients were classified into three phenotypes based on their immunophenotyping characteristics (CD3 cytoplasmic/surface, CD1a, CD4/CD8 expression): early T (16/62, 25.8%), T-intermediate (39/62, 63%), and T- late (7/62, 11.2 %). Comparisons of different phenotypes regarding clinical factors (Age, Sex, initial mediastinal mass), hematological (Hemoglobin, leucocytes counts (TLC), Platelet counts, initial BM blast%), aberrant CD markers (CD10, CD34, CD13/CD33), MRD (Day 15, 33 and 56) and overall survival revealed significant variations regarding: TLC where the highest was T-late phenotype (P= 0.014), MRD D33 (P= 0.039) and MRD D56 (P= 0.007) where T-late phenotype shows a better outcome. CD10 was expressed on 17/62 (27.4%), CD13 and/or CD33 on 10/62 (16.1%), CD34 on 15/62 (24.2%) of cases and co-expression of CD10 and CD34 on 5/62 (8%). Significant associations were found aberrant markers and different phenotypic groups where CD10+CD34+ phenotype and CD13/CD33 occur almost exclusively in early-T groups (P= 0.007 and 0.002 respectively). CD10 shows borderline significant better MRD outcome at D33 (P=0.057) and also slightly better overall survival. CD34 shows significantly worse MRD D33 (P=0.045) but no correlation with OS. Though all five patients with CD10+CD34+ phenotype shows MRD<0.01 by D33 and then after, no significant correlation was found with MRD nor OS; which maybe be explained by small patient number. CD13/CD33 expression shows significant correlation with worse MRD D33 (P=0.017) with worse -but not significant- OS.
Conclusion
Immunophenotypic groups and aberrant expression (CD10, CD34, CD10+CD34 and CD13/CD33) have an important prognostic value in T-ALL, which is evident by their effect on MRD D33, D56 and OS.
Session topic: E-poster
Keyword(s): CD33, CD34, MRD, T-ALL
{{ help_message }}
{{filter}}